NASH is a liver disease characterised by rising prevalence, low diagnosis levels and a lack of therapies currently approved for treatment.

Subscribers to the NASH patient chart audit, which will run in the US and EU5 initially, with other markets available on demand, will be able to understand and track the treatment of NASH as a number of pipeline drugs appear on the market. 

“Given its rising prevalence, low diagnosis levels and lack of approved therapies, NASH is a growing priority for the healthcare industry – and, potentially, a multi-billion-dollar market," said Dr Sabina Heinz, who heads up the monitor.

"The NASH Therapy Monitor will give us deeper insight into the current patient populations and barriers to diagnosis, as well as providing input into forecasts on the potential uptake of new therapies once launched.”